87743-55-3

Upstream product

• 99-03-6 1-(3-aminophenyl)ethanone 
• 79-22-1 methyl chloroformate 
• 67-56-1 methanol 
• 590-28-3 potassium cyanate 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 138835-54-8 2,4,6-trinitrophenyl methyl carbonate 
• 201230-82-2 carbon monoxide 

Downstream Products

• 51648-39-6 [3-(2,4-Dimethyl-[1,3]dioxolan-2-yl)-phenyl]-carbamic acid methyl ester 
• 81263-18-5 [3-(2-Methyl-[1,3]oxathiolan-2-yl)-phenyl]-carbamic acid methyl ester 
• 50427-94-6 [3-(2-Methyl-[1,3]dithiolan-2-yl)-phenyl]-carbamic acid methyl ester 

Relevant academic research and scientific papers

An Exceptionally Mild, Catalytic Homogeneous Method for the Conversion of Amines into Carbamate Esters

Aromatic amines react at room temperature and atmospheric pressure with carbon monoxide, oxygen, alcohols, and hydrochloric acid, with palladium chloride as the catalyst and copper(II) chloride as re-oxidant to give carbamate esters in fair to quantitative yields.

An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors

Sphingosine kinase 1 (SphK1), the enzyme that produces the bioactive sphingolipid metabolite, sphingosine-1-phosphate, is a promising new molecular target for therapeutic intervention in cancer and inflammatory diseases. In view of its importance, the main objective of this work was to find new and more potent inhibitors for this enzyme possessing different structural scaffolds than those of the known inhibitors. Our theoretical and experimental study has allowed us to identify two new structural scaffolds (three new compounds), which could be used as starting structures for the design and then the development of new inhibitors of SphK1. Our study was carried out in different steps: virtual screening, synthesis, bioassays and molecular modelling. From our results, we propose a new dihydrobenzo[b]pyrimido[5,4-f]azepine and two alkyl{3-/4-[1-hydroxy-2-(4-arylpiperazin-1-yl)ethyl]phenyl}carbamates as initial structures for the development of new inhibitors. In addition, our molecular modelling study using QTAIM calculations, allowed us to describe in detail the molecular interactions that stabilize the different Ligand-Receptor complexes. Such analyses indicate that the cationic head of the different compounds must be refined in order to obtain an increase in the binding affinity of these ligands.

Synthesis and in vitro antimycobacterial activity of novel n-arylpiperazines containing an ethane-1,2-diyl connecting chain

Novel 1-(2-{3-/4-[(alkoxycarbonyl)amino]phenyl}-2-hydroxyethyl)-4-(2-fluorophenyl)-piperazin-1-ium chlorides (alkoxy = methoxy to butoxy; 8a-h) have been designed and synthesized through multistep reactions as a part of on-going research programme focused

Synthesis of aryl carbamates via copper-catalyzed coupling of aryl halides with potassium cyanate

Coupling of aryl halides with potassium cyanate takes place at 100-110 °C in alcohols under the catalysis of CuI (cuprous iodide) and 2-(2,6-dimethylphenylamino)-2-oxoacetic acid, affording the corresponding aryl carbamates with great diversity. Copyright

Kinetic study of the reactions of methyl 2,4,6-trinitrophenyl carbonate with anilines

The title reactions in water are subjected to a kinetic investigation. Under excess amine, pseudo-first-order rate coefficients (kobsd) are obtained. Plots of kobsd against aniline concentration are linear, with kN as the slope. The Bronsted-type plot (log kN vs anilinium pK a) is linear with slope 0.7, consistent with a concerted mechanism. By comparison of these reactions with others, it is concluded that anilines destabilize the tetrahedral intermediate relative to isobasic pyridines. The change of 2,4-dinitrophenoxide by 2,4,6-trinitrophenoxide as the leaving group of the carbonate destabilizes the tetrahedral intermediate and makes possible a change in mechanism. ARKAT-USA, Inc.

Aryl and heteroaryl[[7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanones

Novel aryl and heteroaryl[7-(3-substituted amino phenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanones useful as anxiolytic, antiepileptic and sedative-hypnotic agents and as skeletal muscle relaxants, methods of using the novel compounds, compositions containing them and processes for this production.